Literature DB >> 12878545

Quinupristin-dalfopristin resistance in Streptococcus pneumoniae: novel L22 ribosomal protein mutation in two clinical isolates from the SENTRY antimicrobial surveillance program.

Ronald N Jones1, David J Farrell, Ian Morrissey.   

Abstract

Resistance to quinupristin-dalfopristin (Q/D) among gram-positive cocci has been very uncommon. Two clinical isolates among 8,837 (0.02%) Streptococcus pneumoniae isolates were discovered in 2001 to 2002 with Q/D MICs of 4 micro g/ml. Each had a 5-amino-acid tandem duplication (RTAHI) in the L22 ribosomal protein gene (rplV) preventing synergistic ribosomal binding of the streptogramin combination. Similar gene duplication has been reported in Q/D-resistant Staphylococcus aureus.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12878545      PMCID： PMC166062          DOI： 10.1128/AAC.47.8.2696-2698.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States.

Authors:  R N Jones; C H Ballow; D J Biedenbach
Journal:  Diagn Microbiol Infect Dis       Date:  2001 May-Jun       Impact factor: 2.803

2.  Emergence of macrolide resistance during treatment of pneumococcal pneumonia.

Authors:  Daniel M Musher; Mark E Dowell; Virginia D Shortridge; Robert K Flamm; James H Jorgensen; Pierre Le Magueres; Kurt L Krause
Journal:  N Engl J Med       Date:  2002-02-21       Impact factor: 91.245

3.  Resistance to quinupristin-dalfopristin due to mutation of L22 ribosomal protein in Staphylococcus aureus.

Authors:  Brigitte Malbruny; Annie Canu; Bülent Bozdogan; Bruno Fantin; Virginie Zarrouk; Sylvie Dutka-Malen; Celine Feger; Roland Leclercq
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

Review 4.  The era of antimicrobial resistance-implications for the clinical laboratory.

Authors:  D E Low
Journal:  Clin Microbiol Infect       Date:  2002       Impact factor: 8.067

5.  Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999.

Authors:  D J Hoban; G V Doern; A C Fluit; M Roussel-Delvallez; R N Jones
Journal:  Clin Infect Dis       Date:  2001-05-15       Impact factor: 9.079

Review 6.  Resistance among Streptococcus pneumoniae: Implications for drug selection.

Authors:  Peter C Appelbaum
Journal:  Clin Infect Dis       Date:  2002-05-16       Impact factor: 9.079

Review 7.  Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications.

Authors:  Roland Leclercq
Journal:  Clin Infect Dis       Date:  2002-01-11       Impact factor: 9.079

8.  Detection of macrolide resistance mechanisms in Streptococcus pneumoniae and Streptococcus pyogenes using a multiplex rapid cycle PCR with microwell-format probe hybridization.

Authors:  D J Farrell; I Morrissey; S Bakker; D Felmingham
Journal:  J Antimicrob Chemother       Date:  2001-10       Impact factor: 5.790

9.  A European study on the relationship between antimicrobial use and antimicrobial resistance.

Authors:  Stef L A M Bronzwaer; Otto Cars; Udo Buchholz; Sigvard Mölstad; Wim Goettsch; Irene K Veldhuijzen; Jacob L Kool; Marc J W Sprenger; John E Degener
Journal:  Emerg Infect Dis       Date:  2002-03       Impact factor: 6.883

10.  A multicenter evaluation of linezolid antimicrobial activity in North America.

Authors:  Charles H Ballow; Ronald N Jones; Douglas J Biedenbach
Journal:  Diagn Microbiol Infect Dis       Date:  2002-05       Impact factor: 2.803
  10 in total
  6 in total

1.  In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations.

Authors:  David J Farrell; Ian Morrissey; Sarah Bakker; Sylvie Buckridge; David Felmingham
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

2.  Development of Tyrocidine A analogues with improved antibacterial activity.

Authors:  Michael A Marques; Diane M Citron; Clay C Wang
Journal:  Bioorg Med Chem       Date:  2007-08-11       Impact factor: 3.641

3.  Quinupristin-dalfopristin nonsusceptibility in pneumococci from sickle cell disease patients.

Authors:  Caroline A Obert; Martha L Miller; Jeremy Montgomery; Thomas Adamkiewicz; Elaine I Tuomanen
Journal:  Antimicrob Agents Chemother       Date:  2006-10-23       Impact factor: 5.191

4.  Ribosomal mutations as the main cause of macrolide resistance in Campylobacter jejuni and Campylobacter coli.

Authors:  Mirva Lehtopolku; Pirkko Kotilainen; Marjo Haanperä-Heikkinen; Ulla-Maija Nakari; Marja-Liisa Hänninen; Pentti Huovinen; Anja Siitonen; Erkki Eerola; Jari Jalava; Antti J Hakanen
Journal:  Antimicrob Agents Chemother       Date:  2011-09-12       Impact factor: 5.191

5.  Mobile elements and chromosomal changes associated with MLS resistance phenotypes of invasive pneumococci recovered in the United States.

Authors:  Paulina A Hawkins; Sopio Chochua; Delois Jackson; Bernard Beall; Lesley McGee
Journal:  Microb Drug Resist       Date:  2014-08-12       Impact factor: 3.431

Review 6.  Biological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate Vaccine Eras: a United States Perspective.

Authors:  Lindsay Kim; Lesley McGee; Sara Tomczyk; Bernard Beall
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.